Organoid and Human Cell Culture Core for Phage Therapy against antibiotic-resistant bacteria
Official title: Organoid and Primary Culture Core
Funded at J. David Gladstone Institutes · NIH-11265555 · Data updated 2026-11-12
A core facility at a leading research center is developing advanced human-based models to test phage therapies against resistant bacteria, with a focus on Klebsiella pneumoniae.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | J. David Gladstone Institutes NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | May 11, 2026 |
| Project end | April 30, 2031 |
| Funding year | 2026 |
| Award (this year) | $324,500 |
| NIH project number | 1P01AI195327-01 |
| Project ID | NIH-11265555 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with antibiotic-resistant respiratory infections or those at risk of such infections may indirectly benefit from improved therapies developed using these models.
✕Less likely to help
Patients not facing bacterial lung infections may not directly benefit from this core.
What this research studies
The Organoid and Human Cell Culture Core will create and use 3D human airway organoids and 2D air-liquid interface cultures to study how phage therapies interact with human lung tissue. Researchers will establish infection models with Klebsiella pneumoniae and test phage effectiveness and safety in these human-relevant systems. This work aims to speed translation of phage-based treatments into clinical settings by providing more accurate preclinical data. The project addresses a critical need as antibiotic resistance rises and traditional models fall short of predicting human responses.
Why it matters
Potential benefit: If successful, patients could benefit from faster development of effective phage therapies against drug-resistant lung infections.
How similar studies have gone: Similar organoid and ALI culture approaches have shown promise in predicting human responses to therapies in respiratory infections.
Where this research is happening
-
J. David Gladstone Institutes
San Francisco, United States Active
Researchers
- Principal investigator: Ott, Melanie Maria — J. David Gladstone Institutes
- Study coordinator: Ott, Melanie Maria
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.